TEDA Biomedical Relocates Hong Kong Principal Place of Business to Admiralty, Effective 14 September 2026

Bulletin Express
Sep 14

Tianjin TEDA Biomedical Engineering Company Limited announced that its principal place of business in Hong Kong will move to Room 3708, 37/F, Tower 1, Lippo Centre, 89 Queensway, Admiralty, with effect from 14 September 2026.

The company confirmed that its telephone number, fax number and website (www.bioteda.com) remain unchanged.

Executive directors are Sun Li and Yang Zeng; non-executive directors are He Xin, Li Ximing, Wang Lei and Xia Alan Zhe; independent non-executive directors are Gao Chun, Tu Xiangzhen and Chen Jiang.

The announcement was issued on 14 September 2026 and will be available on the Hong Kong Stock Exchange website for seven days and on the company’s website thereafter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10